According to a study published in Psycho‐Oncology, patients with newly diagnosed malignant lymphoma or multiple myeloma who reported depressive symptoms prior to the start of chemotherapy had poorer survival compared with patients who were not initially depressed. The prospective analysis was conducted at the Nagoya City University Hospital in Japan. Researchers sought to investigate the…
Isomaltoside with derisomaltose yielded a more pronounced hematologic response but a similar safety profile compared with iron sucrose.
Continuing warfarin therapy for 18 months after an initial 6-month course decreased incidence of venous thrombosis and major bleeding.
Researchers evaluated whether certain brands of recombinant Factor VIII products were associated with increased risk of developing inhibitors.
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Therapeutic plasma exchange could become an effective mainstay of treatment for immune-mediated thrombotic thrombocytopenic purpura.
Similar rates of thrombotic events occurred in patients with FXII deficiency and unaffected controls.
Hemolytic anemia and immune thrombocytopenic purpura were the most common complications of immune checkpoint inhibitor therapy.
Researchers evaluated response rates to azacitidine and decitabine in patients with chronic myelomonocytic leukemia according to various sets of response criteria.
Researchers described 2 patients with refractory thrombotic thrombocytopenic purpura who regained normal ADAMTS13 levels after splenectomy.
